.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AA13_Pegfilgrastim.Pegfilgrastim .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AA13_Pegfilgrastim.Pegfilgrastim| name: | Pegfilgrastim |
| ATC code: | L03AA13 | route: | subcutaneous |
| n-compartments | 2 |
Pegfilgrastim is a long-acting pegylated form of filgrastim (G-CSF) used to reduce the incidence of infection, as manifested by febrile neutropenia, in patients receiving myelosuppressive chemotherapy. It is approved and widely used today in oncology supportive care.
Population pharmacokinetic parameters in adult cancer patients receiving a 6 mg subcutaneous dose of pegfilgrastim.
Moosavi, S, et al., & Yao, HM (2020). PF-06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta. Advances in therapy 37(7) 3370–3391. DOI:10.1007/s12325-020-01387-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/32524499
Roskos, LK, et al., & Yang, BB (2006). Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects. Journal of clinical pharmacology 46(7) 747–757. DOI:10.1177/0091270006288731 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16809800
Vose, JM, et al., & Liang, BC (2003). Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 21(3) 514–519. DOI:10.1200/JCO.2003.03.040 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12560443